Targeting Indoleamine 2,3-Dioxygenase 1: Fighting Cancers Dormancy Regulation

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Sep 20

PMID 34539663

Citations 5

Authors

Chao Yang

Chan-Tat Ng

Dan Li

Lei Zhang

Affiliations

Soon will be listed here.

Abstract

The connection between indoleamine 2,3-dioxygenase 1 (IDO1) and tumour dormancy - a quiescent state of tumour cells which has been consistently linked to metastasis and cancer recurrence - is rarely discussed despite the pivotal role of IDO1 in cancer development and progression. Whilst the underlying mechanisms of IDO1-mediated dormancy are elusive, we summarize the IDO1 pathways which potentially contribute to dormancy in this review. Critically, distinct IDO1 activities are involved in dormancy initiation and maintenance; factors outside the well-studied IDO1/kynurenine/aryl hydrocarbon receptor axis, including the mammalian target of rapamycin and general control nonderepressible 2, appear to be implicated in dormancy. We also discuss various strategies for cancer treatment regulating IDO1-dependent dormancy and suggest the application of nanotechnology to deliver effective treatment.

Citing Articles

Improving the Anti-Tumor Effect of Indoleamine 2,3-Dioxygenase Inhibitor CY1-4 by CY1-4 Nano-Skeleton Drug Delivery System.

Li H, Liu J, Wang J, Li Z, Yu J, Huang X J Funct Biomater. 2024; 15(12).

PMID: 39728172 PMC: 11676189. DOI: 10.3390/jfb15120372.

Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer.

Yan J, Chen D, Ye Z, Zhu X, Li X, Jiao H Mol Cancer. 2024; 23(1):241.

PMID: 39472902 PMC: 11523861. DOI: 10.1186/s12943-024-02164-y.

Awakening of Dormant Breast Cancer Cells in the Bone Marrow.

Wieder R Cancers (Basel). 2023; 15(11).

PMID: 37296983 PMC: 10252003. DOI: 10.3390/cancers15113021.

Cellular-scale proximity labeling for recording cell spatial organization in mouse tissues.

Zhang X, Tang Q, Sun J, Guo Y, Zhang S, Liang S Sci Adv. 2023; 9(21):eadg6388.

PMID: 37235653 PMC: 10219591. DOI: 10.1126/sciadv.adg6388.

Membrane Internalization Mechanisms and Design Strategies of Arginine-Rich Cell-Penetrating Peptides.

Hao M, Zhang L, Chen P Int J Mol Sci. 2022; 23(16).

PMID: 36012300 PMC: 9409441. DOI: 10.3390/ijms23169038.

References

Goldberg M . Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer. 2019; 19(10):587-602. DOI: 10.1038/s41568-019-0186-9. View

Fallarino F, Grohmann U, Vacca C, Bianchi R, Orabona C, Spreca A . T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002; 9(10):1069-77. DOI: 10.1038/sj.cdd.4401073. View

Cuyas E, Corominas-Faja B, Joven J, Menendez J . Cell cycle regulation by the nutrient-sensing mammalian target of rapamycin (mTOR) pathway. Methods Mol Biol. 2014; 1170:113-44. DOI: 10.1007/978-1-4939-0888-2_7. View

Fu S, Zhang N, Yopp A, Chen D, Mao M, Chen D . TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant. 2004; 4(10):1614-27. DOI: 10.1111/j.1600-6143.2004.00566.x. View

Hennequart M, Pilotte L, Cane S, Hoffmann D, Stroobant V, De Plaen E . Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance. Cancer Immunol Res. 2017; 5(8):695-709. DOI: 10.1158/2326-6066.CIR-16-0400. View

Pang P, Lin Y, Lee Y, Hou H, Hsu S, Juan S . Molecular mechanisms of p21 and p27 induction by 3-methylcholanthrene, an aryl-hydrocarbon receptor agonist, involved in antiproliferation of human umbilical vascular endothelial cells. J Cell Physiol. 2007; 215(1):161-71. DOI: 10.1002/jcp.21299. View

Holmgaard R, Zamarin D, Li Y, Gasmi B, Munn D, Allison J . Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015; 13(2):412-24. PMC: 5013825. DOI: 10.1016/j.celrep.2015.08.077. View

Song W, Shen L, Wang Y, Liu Q, Goodwin T, Li J . Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap. Nat Commun. 2018; 9(1):2237. PMC: 5993831. DOI: 10.1038/s41467-018-04605-x. View

Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S . Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998; 58(17):3761-4. View

10.

Sang W, Zhang Z, Dai Y, Chen X . Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. Chem Soc Rev. 2019; 48(14):3771-3810. DOI: 10.1039/c8cs00896e. View

11.

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

12.

Aguirre-Ghiso J . Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-46. PMC: 2519109. DOI: 10.1038/nrc2256. View

13.

Novak D, Huser L, Elton J, Umansky V, Altevogt P, Utikal J . SOX2 in development and cancer biology. Semin Cancer Biol. 2019; 67(Pt 1):74-82. DOI: 10.1016/j.semcancer.2019.08.007. View

14.

Trabanelli S, Lecciso M, Salvestrini V, Cavo M, Ocadlikova D, Lemoli R . PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response. J Immunol Res. 2015; 2015:253191. PMC: 4357138. DOI: 10.1155/2015/253191. View

15.

Liu C, Okayasu T, Goldman P, Suzuki Y, Suzuki K, Wheelock E . Immune regulation of the L5178Y murine tumor-dormant state. I. In vivo and in vitro effects of prostaglandin E2 and indomethacin on tumor cell growth. J Exp Med. 1986; 164(4):1259-73. PMC: 2188415. DOI: 10.1084/jem.164.4.1259. View

16.

Sauer S, Bruno L, Hertweck A, Finlay D, Leleu M, Spivakov M . T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A. 2008; 105(22):7797-802. PMC: 2409380. DOI: 10.1073/pnas.0800928105. View

17.

Konkel J, Zhang D, Zanvit P, Chia C, Zangarle-Murray T, Jin W . Transforming Growth Factor-β Signaling in Regulatory T Cells Controls T Helper-17 Cells and Tissue-Specific Immune Responses. Immunity. 2017; 46(4):660-674. DOI: 10.1016/j.immuni.2017.03.015. View

18.

Holtzhausen A, Zhao F, Evans K, Tsutsui M, Orabona C, Tyler D . Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. Cancer Immunol Res. 2015; 3(9):1082-95. PMC: 4927300. DOI: 10.1158/2326-6066.CIR-14-0167. View

19.

Munn D, Sharma M, Baban B, Harding H, Zhang Y, Ron D . GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005; 22(5):633-42. DOI: 10.1016/j.immuni.2005.03.013. View

20.

Pallotta M, Orabona C, Volpi C, Vacca C, Belladonna M, Bianchi R . Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 2011; 12(9):870-8. DOI: 10.1038/ni.2077. View